✦ LIBER ✦

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

✍ Scribed by Scheithauer, W; Kornek, G V; Raderer, M; Hejna, M; Valencak, J; Miholic, J; Kovats, E; Lang, F; Funovics, J; Bareck, E

Book ID: 110002387
Publisher: Nature Publishing Group
Year: 1999
Tongue: English
Weight: 83 KB
Volume: 80
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6690600

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II trial of dexverapamil, epirub

Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage–colony stimulating factor in patients with advanced pancreatic adenocarcinoma

✍ Gabriela Kornek; Markus Raderer; Thomas Schenk; Johann Pidlich; Franz Schulz; Se 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 659 KB

A phase I/II multicentric trial of gemci

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

✍ Eickhoff, A; Martin, W; Hartmann, D; Eickhoff, J C; Möhler, M; Galle, P R; Riema 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 73 KB

A phase II trial of gemcitabine plus cap

A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma

✍ Byeong-Bae Park; Joon Oh Park; Hyo Rak Lee; Jeeyun Lee; Dong Wook Choi; Seong-Ho 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 243 KB

Phase II trial of edatrexate in patients

Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma

✍ Ephraim S. Casper; Gary K. Schwartz; Bruce Johnson; David P. Kelsen 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 293 KB

Phase I trial of mitoxantrone and granul

Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies

✍ Joan H. Schiller; Barry Storer; Rhoda Arzoomanian; Kendra Tutsch; Dona Alberti; 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 806 KB

Phase II trial of subcutaneously adminis

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have